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Abstract
Background: Airway remodelling is thought to be under the control of a complex group of molecules belonging to 
the Transforming Growth Factor (TGF)-superfamily. The Bone Morphogenetic Proteins (BMPs) belong to this family and 
have been shown to regulate fibrosis in kidney and liver diseases. However, the role of BMPs in lung remodelling 
remains unclear. BMPs may regulate tissue remodelling in asthma by controlling TGF-β-induced profibrotic functions in 
lung fibroblasts.
Methods: Cell cultures were exposed to TGF-β1 alone or in the presence of BMP-4 or BMP-7; control cultures were 
exposed to medium only. Cell proliferation was assessed by quantification of the incorporation of [3H]-thymidine. The 
expression of the mRNA encoding collagen type I and IV, tenascin C and fibronectin in normal human lung fibroblasts 
(NHLF) was determined by real-time quantitative PCR and the main results were confirmed by ELISA. Cell differentiation 
was determined by the analysis of the expression of α-smooth muscle actin (α-SMA) by western blot and 
immunohistochemistry. The effect on matrix metalloproteinase (MMP) activity was assessed by zymography.
Results: We have demonstrated TGF-β1 induced upregulation of mRNAs encoding the extracellular matrix proteins, 
tenascin C, fibronectin and collagen type I and IV when compared to unstimulated NHLF, and confirmed these results 
at the protein level. BMP-4, but not BMP-7, reduced TGF-β1-induced extracellular matrix protein production. TGF-β1 
induced an increase in the activity of the pro-form of MMP-2 which was inhibited by BMP-7 but not BMP-4. Both BMP-4 
and BMP-7 downregulated TGF-β1-induced MMP-13 release compared to untreated and TGF-β1-treated cells. TGF-β1 
also induced a myofibroblast-like transformation which was partially inhibited by BMP-7 but not BMP-4.
Conclusions: Our study suggests that some regulatory properties of BMP-7 may be tissue or cell type specific and 
unveil a potential regulatory role for BMP-4 in the regulation of lung fibroblast function.
Background
Asthma is a chronic inflammatory disorder of the airways
characterized by structural changes of the airway wall,
collectively named remodelling. Airway remodelling is
characterized by subepithelial fibrosis, with thickening of
the subepithelial basement membrane, fibroblast and
myofibroblast accumulation, increased expression of
fibrogenic growth factors, and augmented extracellular
matrix (ECM) deposition in the subepithelial areas of the
proximal airways [1-3]. Other features of airway remodel-
ling include an increase in airway smooth muscle (ASM)
mass caused by hypertrophy and hyperplasia, goblet cell
hyperplasia, and angiogenesis [1-3]. Resident lung fibro-
blasts and myofibroblasts are the primary source of ECM
proteins which are released under the influence of growth
factors such as Transforming Growth Factor (TGF)-β
superfamily members [4,5].
The TGF-β superfamily of ligands comprises more than
35 members in mammals, including TGF-β1-3, activins
and Bone Morphogenetic Proteins (BMPs), which are the
largest subgroup of structurally and functionally related
proteins of this family [6]. TGF-β contributes to airway
remodelling in asthma via induction of a multitude of
responses in lung resident cells. These include apoptosis
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of epithelial cells, dysregulation of epithelial cell adhesion
properties leading to damage of the epithelial cell layer
[7], and enhancement of goblet cell proliferation and
mucus hyper-secretion [5,8]. TGF-β also induces differ-
entiation of fibroblasts into myofibroblasts and their sub-
sequent proliferation, as well as collagen and other ECM
protein production including tenascin-C (Tn-C) and
fibronectin by these cells [9-11]. Tn-C is a purported
marker of reactivation of the epithelial-mesenchymal
trophic unit (EMTU) in asthma. Transient increase of
Tn-C in the asthmatic airway following allergen challenge
has been identified [12], and increased production of
fibronectin by myofibroblasts may promote epithelial-
mesenchymal transition in-vivo  [13]. TGF-β also
enhances proliferation of ASM cells and contributes to
increased ASM mass [14,15]. Anti-TGF-β treatment has
been found to prevent these airway remodelling changes
in a murine model of chronic allergen challenge model
[8,16].
The BMPs are a large class of multifunctional growth
factors and are a major developmental signalling pathway
critical for embryogenesis and tissue generation in organs
such as the kidney and lung [17]. However, they are also
essential during postnatal life, and regulate cell prolifera-
tion, differentiation, apoptosis, angiogenesis, and secre-
tion of ECM components [17,18]. BMP-7 is thought to
have inhibitory effects since it is able to counteract TGF-
β1-induced fibrotic effects in vitro and to reverse estab-
lished fibrosis in organs as diverse as the kidney, heart
and colon [19-26]. However, these antifibrotic effects may
be tissue and indeed cell specific since BMP-7 has no
effect in a bleomycin-induced lung fibrosis model or on
skin fibrosis [27], and does not reverse TGF-β1-induced
epithelial-to-mesenchymal transition in human renal
proximal tubule epithelial cells [28]. In contrast, little is
known about the role of BMP-4 in vitro or in vivo in lung
remodelling although previous studies have shown that
BMP-4 inhibits proliferation and promotes myocyte dif-
ferentiation of lung fibroblasts [29,30]. We recently dem-
onstrated for the first time the presence of BMP-4 and
BMP-7 as well as their receptors in the airways of adult
asthmatics [31]. In this study, BMP receptor expression
was down-regulated in asthmatic airways compared to
healthy controls which may impede repair responses,
although allergen provocation increased expression of
BMP-7, activated BMP signalling and increased receptor
expression in the asthmatic airways, all of which may
contribute to repair [31]. The cellular targets and regula-
tory mechanisms activated by the BMPs remain to be
determined and nothing is known about their function in
the adult lung.
We hypothesised that BMP-4 and BMP-7 may regulate
airway remodelling by inhibiting TGF-β1 effects in lung
fibroblasts. Our results indicate that BMP-4, but not
BMP-7, inhibits TGF-β1 induced cell proliferation of nor-
mal human lung fibroblasts (NHLF) and also blocks the
production of ECM proteins by these cells. Both BMP-4
and BMP-7 inhibited the differentiation of fibroblasts
into myofibroblasts and blocked the release of matrix
metalloproteinase (MMP)-13, whereas only BMP-7 was
able to inhibit TGF-β1-induced MMP-2 activity. In con-
clusion, BMP-4 acts as a potent negative regulator of
TGF-β1 whereas BMP-7 is only partially effective in our
in vitro model of fibroblast activation.
Methods
Normal human lung fibroblast culture and stimulation
Primary adult human lung fibroblasts obtained from
healthy, non-smoking donors, (NHLF, Lonza Rockland
Inc, Rockland, ME, USA) were seeded in 12-well plastic
culture dishes (Sigma-Aldrich, Gillingham, Dorset, UK)
and grown at 37°C in a humidified 5% CO2 atmosphere in
fibroblast growth medium (FGM, Lonza Rockland Inc,
Rockland, ME, USA) supplemented with 0.5 ml recombi-
nant human fibroblast growth factor-B, 0.5 ml insulin, 0.5
ml gentamicin sulphate amphotericin-B and 2% foetal
bovine serum (FBS). Once they reached 80% confluence,
NHLF were stimulated for 24 h, 48 h and 72 h with either
5 ng/ml TGF-β1 or 100 ng/ml human recombinant BMP-
4 or BMP-7 (R&D Systems Europe Ltd., Abingdon, UK).
Cells were also stimulated with 5 ng/ml TGF-β1 in com-
bination with either 100 ng/ml BMP-4 or BMP-7. Those
concentrations are based on previously published data
obtained in other cell types [24,32]
Assessment of NHLF viability and proliferation
The effect of TGF-β1 and BMPs on NHLF viability was
determined by colorimetric MTT based assay (Cell Pro-
liferation Kit I [MTT]; Roche Diagnostics Ltd, West Sus-
sex, UK) according to the manufacturer's instructions.
Briefly, NHLF were seeded in 96-well plates (Sigma-
Aldrich, Dorset, UK) and stimulated as described above
for 24, 48, and 72 h in FGM with or without 2% FBS. Cells
were labelled by 4 h incubation in MTT labelling agent at
37°C and then solubilisation solution was added over-
night. The plates were read on a Microplate reader pho-
tometer at 600-nm wavelength. Three independent
experiments were conducted. For proliferation experi-
ments, fibroblasts were stimulated as above for 36 h with
addition of [3H]-thymidine (1 μCi/ml) for the final 6 h of
incubation. Incorporation of [3H]-thymidine was termi-
nated by washing the cells twice with PBS. Cells were
then lysed with 0.1 N NaOH, and radioactivity (degrada-
tion/minute) measured by a scintillation counter and
used as an index of DNA synthesis and fibroblast prolifer-
ation, five independent experiments were conducted.Pegorier et al. Respiratory Research 2010, 11:85
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RNA isolation and reverse transcription
Confluent NHLF that had been stimulated for 24 h were
recovered in 350 μl lysis buffer RLT contained in the
RNeasy Mini Kit (Qiagen, West Sussex, UK) supple-
mented with 1% 2-βmercaptoethanol (Sigma-Aldrich,
Gillingham, Dorset, UK) and then stored at -80°C. Total
RNA was isolated using this same kit according to manu-
facturer's instructions. Reverse transcription was per-
formed for 2 h at 37°C using Moloney murine leukemia
virus reverse transcriptase (Promega UK, Southampton,
UK) and 1 μg total RNA in 50 μl volume.
Real-time quantitative PCR
Real-time quantitative PCR was performed using the
SYBRGreen JumpStart Taq  Ready Mix detection kit
(Sigma-Aldrich, Gillingham, Dorset, UK). In all assays,
cDNA was amplified using a standardized program (2
min JumpStart Taq Polymerase activation step at 94°C; 40
cycles of 30 s at 94°C and 1 min at 60°C). All assays were
performed in a volume of 20 μl, and primers were used at
a final concentration of 0.33 μM. Reactions were con-
ducted using the PCR ABI 7500 apparatus (Applied Bio-
systems, Warrington, UK). For a more accurate and
reliable normalization of the results, the intensity of gene
expression was normalized to the geometrical mean of
the levels of transcripts encoding the 3 most stable
housekeeping genes: ubiquitin-C (UBC), succinate dehy-
drogenase (SDHA), and ribosomal protein 13a (RPL13a)
[33]. Normalization and calculation were assessed using
the GeNorm method [33]. Primers were designed using
Primer Express 2 Software (Applied Biosystems, War-
rington, UK) and were synthesized by Invitrogen Life
Technologies Ltd. (Paisley, UK). Primer sequences and
basal gene expression in unstimulated NHLF are
described in Table 1.
Determination of total soluble collagen, tenascin C and 
fibronectin in cell supernatant
The levels of total soluble collagen, tenascin C and
fibronectin were assessed in supernatants from NHLF
stimulated for 48 h, and 72 h with TGF-β1 and BMP-4 or
BMP-7 as described. Soluble collagen was measured by
Sircol assay (Biocolor Ltd., County Antrim, UK) and tena-
scin C and fibronectin by ELISA (Human Tenascin-C
Large kit from Immuno-Biological Laboratories, Gunma,
Japan and Fibronectin ELISA reagent kit from Techno-
clone Ltd., Surrey, UK). The threshold of detection was
2.5 μg/ml for total soluble collagen, 0.38 ng/ml for tenas-
cin C and 250 ng/ml for fibronectin.
MMP activation and production
MMP-1 and MMP-2 activation was quantified by gelatin
zymography. Proteins of cell supernatants were separated
on a 10% acrylamide/0.1% gelatin gel (Invitrogen Life
Technologies Ltd., Paisley, UK). After electrophoresis, the
gel was washed twice for 30 min in a buffer containing
2.7% Triton X-100 at room temperature and incubated
for 48 h in 50 mM Tris-base, 40 mM HCl, 200 mM NaCl,
5 mM CaCl2, 0.02% Brij 35, at 37°C. The gels were then
stained with Coomassie brilliant blue and analysed.
Bands were quantified by densitometry with ImageJ soft-
ware. Levels of MMP-13 were quantified in supernatants
from NHLF stimulated for 72 h by ELISA (Collagenase-3
ELISA Kit from Merck Chemicals Ltd. Nottingham, UK).
The threshold of detection was 32 pg/ml.
αSMA immunostaining
To determine whether BMPs can counteract TGF-β1-
induced myofibroblast formation, NHLF were grown on
chamber slides (ICN, Basingstoke, U.K) for 3 days until
~70% confluent and cells were stimulated as described
above for 72 h, washed with PBS and fixed with 4% para-
Table 1: Real-time primer sequences and basal levels of transcript expression in normal human lung fibroblasts
GenBank Identifier Gene Forward Primer Reverse Primer Basal Ct
NM_001105 ALK-2 CGGGAGATGACCTGTAAGACCCCG GGGCCGTGATGTTCCTGTTAC 25.00 ± 0.70
NM_004329 ALK-3 CAGAAACCTATTTGTTCATCATTTCTCG ATCCCAGTGCCATGAAGCATAC 21.97 ± 0.82
NM_001203 ALK-6 CGAATGGGGTGTAGGTCTTTATTACATTCG CCCATTCCTCATCAAAGAAGATCA 26.50 ± 0.93
NM_001204 BMPRII CGGTTTCCACCTCATTCATTTAACCG ACAGAGACTGATGCCAAAGCAAT 24.93 ± 0.42
NM_000088 COL1a1 CTTTGCATTCATCTCTCAAACTTAGTTTT CCCCGCATGGGTCTTCA 19.03 ± 0.69
NM_001845 COL4a1 CTAATCACAAACTGAATGACTTGACTTCA AAATGGCCCGAATGTGCTTA 19.87 ± 0.95
X02761 Fibronectin TGGACCAGAGATCTTGGATGTTC CGCCTAAAACCATGTTCCTCAA 21.70 ± 0.79
X56160 Tenascin C GGTCCACACCTGGGCATTT TTGCTGAATCAAACAACAAAACAGA 17.00 ± 0.92
NM_001613 αSMA CCGACCGAATGCAGAAGGA ACAGAGTATTTGCGCTCCGAA 20.60 ± 0.10
NM_021009 UBC CACTTGGTCCTGCGCTTGA TTTTTTGGGAATGCAACAACTTT 17.50 ± 1.35
NM_012423 RPL13A CCTGGAGGAGAAGAGGAAAGAGA TTGAGGACCTCTGTGTATTTGTCAA 19.65 ± 0.31
NM_004168 SDHA TGTGTCCATGTCATAACTGTCTTCATA AAGAATGAAGCAAGGGACAAAGG 19.00 ± 0.91Pegorier et al. Respiratory Research 2010, 11:85
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formaldehyde. Following permeabilization in PBS con-
taining 0.1% saponin, endogenous peroxidases were
removed by 45 min incubation in peroxidase blocking
solution (DAKO, Glostrup, Denmark) and avidin and bio-
tin were blocked using the avidin/biotin blocking kit
(Vector Laboratories Inc., Burlingame, UK). The slides
were then stained with a rabbit polyclonal anti-SMA anti-
body (Ab) diluted in PBS containing 0.1% saponin and
10% normal human serum for 1 h at room temperature (2
μ g / m l ,  A b c a m ,  C a m b r i d g e ,  U K ) .  A f t e r  w a s h e s  i n  P B S ,
slides were incubated with a biotinylated goat anti-rabbit
Ab (6.5 μg/ml; Stratech Scientific Unit, Newmarket Suf-
folk, UK) for 45 min at room temperature. A third layer of
soluble complexes of StreptABComplex/HRP (DAKO,
Glostrup, Denmark) was incubated for an additional 30
min and developed with peroxidase substrate kit DAB
(Vector Laboratories Inc., Burlingame, California, USA).
Fibroblasts were counterstained with Harris' hematoxylin
(VWR, Leicestershire, UK) and mounted in faramount
aqueous mounting medium (DAKO, Glostrup, Den-
mark). Images were acquired using a Leica TCS SP confo-
cal microscope (Heidelberg, Germany). Substitution of
the primary Ab with an irrelevant isotype-matched Ab of
the same species was used as a negative control.
Western blotting
C o n f l u e n t  N H L F  w e r e  s t i m u l a t e d  a s  b e f o r e  t h e n  h a r -
vested using RIPA buffer (Invitrogen) following the man-
ufacturer's instructions. Protein concentration was
determined using the BCA protein assay (Pierce), against
a bovine serum albumin standard curve.
15 μg protein samples were separated on 10% Bis-Tris
gels in MOPS SDS Running Buffer (Invitrogen), trans-
ferred to polyvinylidene difluoride membrane (Bio-Rad)
and probed with a rabbit polyclonal anti-α-SMA Ab (1/
1000 dilution; AbCam). Immunoblots were then incu-
bated with peroxidase-conjugated goat anti-rabbit IgG
(1/2000 dilution, DakoCytomation) and developed using
the ECL + Western blotting detection system (Amer-
sham). Blots were stripped and re-probed with a mouse
monoclonal anti-vimentin antibody (1/2000 dilution,
Sigma), to ensure equal protein loading.
Transfection and promoter assays
The connective tissue growth factor (CTGF) promoter-
(pCT-sb, 2 μg) Luciferase plasmid and Renilla luciferase
control reporter vector (phRL-TK, 5 ng) were transfected
into NHLF, seeded in 6-well plates, with PrimeFect I
DNA Transfection Reagent (1:10 dilution, Lonza Rock-
land Inc, Rockland, ME, USA) diluted in serum free
FGM. Transfection medium was changed after 24 h to
0.2% FBS containing 5 ng/ml TGF-β1 alone, or 100 ng/ml
BMP-4 or BMP-7 alone or 5 ng/ml TGF-β1 and 100 ng/
ml BMP-4 or BMP-7. After 24 h, luciferase activity was
measured by the dual luciferase assay system (Promega
UK, Southampton, UK) according to manufacturer's
instruction using a TopCount.NXT microplate lumines-
cence counter (PerkinElmer Life, Milano, Italy). Firefly
luciferase activity was normalized by the activity of the
Renilla luciferase under the control of thymidine kinase
promoter of phRL-TK. Results are given as relative light
units. MFB-F11 cells (mouse fibroblasts isolated from
Tgfb1-/- mice stably transfected with TGF-β responsive
Smad-binding elements coupled to a secreted alkaline
phosphatase reporter gene, SBE-SEAP plasmid [34]) were
seeded at 4 × 104 cells/well in 96-well plates. After 4 h in
DMEM containing 10% FBS, cells were incubated with
TGF-β1 and/or BMP-4 and BMP-7 as described for 24 h
in 100 μl of serum free DMEM. All the conditions were
tested in duplicate. SEAP activity was measured in 10 μl
culture supernatant using Great EscAPe SEAP Reporter
System 3 (Clontech Laboratories, Inc., California, USA)
according to the manufacturer's instructions with a
microplate luminescence counter.
Statistical analysis
Data were analyzed using Prism 4.0 for Windows (Graph-
Pad Software Inc.) using Friedman test and Wilcoxon
post test. The results are expressed as means ± SEM for
the indicated number of experiments. The Spearman
rank-order method was assessed to determine correla-
tions between the different molecules studied.
Results
BMP receptor expression in NHLF
In order to confirm the ability of NHLF to respond to the
BMPs, we determined the basal expression of mRNA
encoding the BMP receptors. Unstimulated adult NHLF
expressed the BMP type I receptors Activin receptor-like
kinase (ALK)-2, ALK-3 and ALK-6 as well as the type II
receptor, BMPRII, at the mRNA level as shown in Table 1.
The transcripts encoding ALK-2, ALK-3 and ALK-6 were
not modulated (Figures 1A, B and 1C) whereas mRNA
for BMPRII was significantly up-regulated by TGF-β1,
BMP-4 and BMP-7 (Figure. 1D).
TGF-β superfamily members do not affect NHLF viability 
and proliferation
Cell viability was determined by MTT assay to verify that
the concentrations of TGF-β1 and BMPs used were not
toxic to NHLF. None of the conditions tested affected via-
bility of NHLF in FGM media with or without 2% FBS
(data not shown). Fibroblast and myofibroblast prolifera-
tion and accumulation in the sub-epithelial area is a fea-
ture of lung remodelling. Therefore, we determined the
effect of TGF-β family members on proliferation of
NHLF. TGF-β1, BMP-4 and BMP-7 had no effect on cell
proliferation as compared to untreated-cells. However,Pegorier et al. Respiratory Research 2010, 11:85
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the addition of BMP-4, but not BMP-7, to TGF-β1-stimu-
lated NHLF led to a significant decrease in cell prolifera-
tion as compared to either untreated or TGF-β1-
stimulated cells (Figure 2).
BMP-4, but not BMP-7, downregulates TGF-β1-induced 
ECM protein expression
There is extensive published literature describing TGF-
β1-driven ECM production in the airways as well as the
contribution of fibroblasts to the thickness of the sub-
basement membrane, however the role of BMPs in this
phenomenon is not yet described in the lung. Incubation
of NHLF for 24 h in the presence of 5 ng/ml TGF-β1 sig-
nificantly up-regulated the expression of mRNAs encod-
ing collagen types I and IV (10- and 9-fold increase,
respectively, Figures 3A and 3B). The increase in mRNA
transcripts correlated with increased synthesis and
release of total soluble collagen measured in cell superna-
tants (Figure 3C). Transcripts for tenascin C and
fibronectin were also upregulated by TGF-β1 (11- and
2.5-fold increase, respectively, Figures 4A and 4C). This
increase was reflected at the protein level (18- and 1.7-
fold increase, Figures 4B and 4D, respectively), as deter-
mined by specific ELISA. In contrast, BMP-4 and BMP-7
(100 ng/ml) did not affect expression of the transcripts
encoding collagen type I or IV (Figures 3A and 3B), or
fibronectin (Figure 4C). However, a moderate but signifi-
cant induction of the mRNA for tenascin C was mea-
sured after incubation of NHLF with both BMP-4 and
BMP-7 (Figure 4A). BMP-4 inhibited the TGF-β1-
induced increase in the level of the transcripts encoding
collagen type I and IV (Figures 3A and 3B), tenascin and
fibronectin (Figures 4A and 4C). A similar effect was
observed at the protein level with a 50% decrease in total
soluble collagen synthesis (Figure 3C), inhibition of the
release of tenascin C and fibronectin (30% and 20%,
respectively, Figures 4B and 4D). In contrast, BMP-7 did
not modify the TGF-β1-induced up-regulation of the
transcripts and proteins examined except for a significant
suppression of the expression of mRNA for tenascin C
(Figure 4A) but this result was not confirmed at the pro-
tein level (Figure 4B).
TGF-β family members modulate collagenase and 
gelatinase activities and expression
The ECM accumulation observed in the asthmatic lung
can result from an increase in ECM protein production
Figure 2 Simultaneous incubation of NHLF with TGF-β1 and 
BMP-4 inhibits cell proliferation. [3H]thymidine incorporation in 
NHLF in response to tissue culture media with 2% FBS in the presence 
of 5 ng/ml TGF-β1 or 100 ng/ml BMP-4 or BMP-7 alone or with TGF-β1 
in the presence of BMP-4 or BMP-7 for 36 h. [3H]thymidine was added 
for the last 6 h of incubation. Data are mean ± SD of five independent 
experiments. *, p < 0.05, as compared to unstimulated cells and †, p < 
0.05, as compared to TGF-β1-stimulated cells.
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Figure 1 Effect of TGF-β superfamily members on BMP type I and 
type II receptor transcript levels. NHLF were stimulated with 5 ng/
ml TGF-β1 or 100 ng/ml BMP-4 or BMP-7 for 24 h. Cells were harvested, 
RNA extracted and reverse transcribed, and a real-time quantitative 
PCR for ALK-2 (A), ALK-3 (B), ALK-6 (C), and BMPRII (D) was performed. Re-
sults are expressed as the ratio of each transcript relative to the geo-
metric mean of mRNA expression of the housekeeping genes UBC, 
SDHA, and RPL13a. Data are mean ± SD of five independent experi-
ments. *, p < 0.05, as compared to unstimulated cells.
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and/or a deregulation in proMMP activities, the activa-
tion of these proenzymes being a critical step that leads to
ECM breakdown. NHLF were stimulated for 72 h with
either TGF-β1, BMP-4 or BMP-7 or TGF-β1 in combina-
tion with BMP-4 or BMP-7, and MMP activity in the cell
supernatants was detected on gelatine gels by zymogra-
phy. Both TGF-β1 and BMP-4 led to a moderate but sig-
nificant increase in the gelatinolytic activity of the pro-
forms of MMP-1 (57 and 52 kDa, Figure 5A) and MMP-2
(72 kDa, Figure 5B) whereas the activity of the active
forms was not modulated (47 and 42 kDa for MMP-1 and
67 kDa for MMP-2). BMP-7 itself did not alter the expres-
sion of MMP-1 or MMP-2 but its addition to TGF-β1-
stimulated cells led to a significant down-regulation in
the activity of the pro-MMP-2 as compared to cells stim-
ulated with TGF-β1 alone (Figure 5B). MMP-9 activity
was not detected, regardless of the stimulation condi-
tions. MMP-13 release from NHLF was decreased in the
presence of BMP-4 and BMP-7 compared to untreated-
or TGF-β1-stimulated cells (Figure 5C). The inhibition of
MMP-13 release was of similar magnitude when the
BMPs were incubated in the presence of TGF-β. Increas-
ing the concentration of BMPs to 1 μg/ml did not result in
further MMP-13 reductions (data not shown).
TGF-β1-induced fibroblast differentiation is partially 
inhibited by BMP-7
Fibroblast differentiation into myofibroblasts is crucial in
tissue remodelling, wound healing, and various fibrotic
disorders in the lung and the contribution of TGF-β to
this phenomenon in vitro is well documented [5,11,35].
Here we characterized the effect of BMP-4 and BMP-7 on
the induction of a myofibroblast-like phenotype in nor-
mal lung fibroblasts exposed to TGF-β1. In culture,
NHLF basally expressed low levels of αSMA as demon-
strated by immunohistochemistry (first panel, Figure 6A).
Stimulation with TGF-β1 led to a discernable increase in
α-SMA+ cell number (Figure 6B). Western blot of NHLF
cell lysates confirmed our observations. Incubation with
BMP-4 also led to an increase in the number of αSMA+
cells, whereas BMP-7 alone had no effect (Figure 6A and
6B). BMP-4 did not affect TGF-β1 driven α-SMA expres-
sion. In contrast, BMP-7 significantly inhibited TGF-β1
induced differentiation (Figure 6A and 6B).
BMPs do not affect TGF-β1-induced CTGF promoter and 
Smad-Binding Element reporter gene activities
In order to determine the mechanism by which BMPs
counteract TGF-β1 effects, activity assays were per-
formed on the CTGF promoter (pCT-sp) transfected in
NHLF and TGF-β responsive Smad-binding elements
(SBE) reporter gene in the MFB-F11 cell line. TGF-β1
increased luciferase activity in the pCT-sp 6-fold, indica-
tive of CTGF promoter activity (Figure 7A) and SEAP
activity in the SBE-SEAP reporter 37-fold (Figure 7B) and
this response to TGF-β was not inhibited by either BMP-
4 or BMP-7. BMP-4 moderately increased pCT-sp activ-
ity (3.6-fold induction, Figure 7A) demonstrating that
BMP-4 partially acts via increasing CTGF promoter
activity. In contrast, the BMPs had no direct effect on the
SBE-SEAP reporter, indicating that they are not able to
inhibit binding of phosphorylated Smads (downstream
signalling molecules of TGF-β1) to the Smad-Binding
Element present on many genes regulated by TGF family
members.
Figure 3 TGF-β1-induced collagen expression in NHLF is downregulated by BMP-4. NHLF were stimulated with 5 ng/ml TGF-β1 or 100 ng/ml 
BMP-4 or BMP-7 alone, or with TGF-β1 in the presence of BMP-4 or BMP-7 for 24 h (A and B) or 72 h (C). Cells were harvested, RNA was extracted, reverse 
transcribed, and a real-time quantitative PCR for collagen type I alpha 1 chain (COL1a1, A) and collagen type IV alpha 1 chain (COL4a1, B) was per-
formed. Results are expressed as the ratio of each transcript relative to the geometric mean of mRNA expression of the housekeeping genes UBC, SD-
HA, and RPL13a. Total soluble collagen release was quantified in the cell supernatants by Sircol assay (C). Data are mean ± SD of five independent 
experiments. *, p < 0.05, as compared to unstimulated cells and †, p < 0.05, as compared to TGF-β1-stimulated cells.
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Discussion
In the current study, we determined the ability of two
Bone Morphogenetic Proteins, BMP-4 and BMP-7, to
modulate the profibrotic effects of TGF-β1 on NHLF. We
found that BMP-4 and BMP-7 are able to regulate the
synthesis and production of ECM proteins, MMPs and α-
SMA in primary lung fibroblasts. BMP-4 inhibits TGF-
β1-induced cell proliferation and ECM protein release.
Both BMP-4 and BMP-7 decreased MMP-13 release in
TGF-β1-stimulated cells. In contrast, only BMP-7 inhib-
ited myofibroblast differentiation and activation of
MMP-2 induced by TGF-β1. We have also shown that
TGF-β1 can act directly on the BMP pathways by increas-
ing expression of the mRNA encoding ALK-6 and
BMPRII.
The ECM is known to be involved in a variety of cellu-
lar processes, including morphogenesis, lung remodel-
ling, and modifications in cell shape that occur during
differentiation of a number of lung structural cells [5,36].
As a result, changes in the composition of the ECM can
profoundly affect the behaviour of cells and lead to airway
remodelling in lung fibrotic diseases, including asthma.
The increase in ECM deposition results from either
increased production or decreased breakdown of matrix
Figure 4 TGF-β1-induced ECM protein expression in NHLF is down-regulated by BMP-4. NHLF were stimulated with 5 ng/ml TGF-β1 or 100 ng/
ml BMP-4 or BMP-7 alone or with TGF-β1 in the presence of BMP-4 or BMP-7 for 24 h (A and B) or 48 h (C and D). Cells were harvested, RNA was ex-
tracted, reverse transcribed, and a real-time quantitative PCR for tenascin C (A) and fibronectin (C) was performed. Results are expressed as the ratio of 
each transcript relative to the geometric mean of mRNA expression of the housekeeping genes UBC, SDHA, and RPL13a. Tenascin C and fibronectin 
protein were quantified in the cell supernatants by specific ELISAs (B and D, respectively). Data are mean ± SD of five independent experiments. *, p 
< 0.05, as compared to unstimulated cells and †, p < 0.05, as compared to TGF-β1-stimulated cells.
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products. Deregulation of the proteolytic-antiproteolytic
network and inappropriate secretion of various MMPs by
stimulated lung structural cells is thought to be involved
in the pathophysiology of asthma [37]. The contribution
of TGF-β1 to ECM accumulation, and to fibroblast differ-
entiation and proliferation has been widely reported
[5,35,38,39]. Its action is mainly driven by activation of
CTGF, resulting in stimulation of fibroblast proliferation,
myofibroblast differentiation and collagen synthesis
[40,41]. In this study, we confirmed the ability of TGF-β1
to induce production of the ECM proteins collagen types
I and IV, fibronectin and tenascin C, and to induce myofi-
broblastic differentiation. However, we did not observe
TGF-β1-induced fibroblast proliferation as previously
reported by some groups [9,42,43] but those data might
be considered controversial since the effect of TGF-β1 on
fibroblast proliferation is dependent on its concentration
[44]. The increased expression of αSMA correlates with
the release of collagen and activation of MMP-1, the
major enzyme involved in degradation of native collagen,
which is in accordance with the data showing that myofi-
broblasts are the major source of collagen type I in the
lung [45]. Finally we confirmed the ability of TGF-β1 to
activate both the CTGF promoter and Smad-binding ele-
Figure 5 Effect of TGF-β superfamily members on MMP activity and expression level. NHLF were stimulated with 5 ng/ml TGF-β1 or 100 ng/ml 
BMP-4 or BMP-7 alone or with TGF-β1 in the presence of BMP-4 or BMP-7 for 72 h. Cell supernatants were collected to perform zymography (A and B) 
and ELISA (C). Representative gelatin zymograms and related graphic plot of the bands obtained in zymographs for the pro-forms of MMP-1 (A) and 
MMP-2 (B) were performed. Gelatinolytic activity of the pro- and active forms of MMP-1 (57/52 and 47/42 kDa) and pro- and active forms of MMP-2 
(72 and 67 kDa) are indicated. MMP-13 release was quantified in the cell supernatants by specific ELISA (C). Data are mean ± SD of five independent 
experiments. *, p < 0.05, as compared to unstimulated cells and †, p < 0.05, as compared to TGF-β1-stimulated cells.
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ments (SBE) contained in the promoter region of more
than 500 target genes responding to TGF-β1 [34].
In most models and cell types, BMP-7 opposes TGF-
β1-mediated ECM protein production in vivo and in vitro
[19-26]. BMP-7 regulates the ECM breakdown in human
chondrocytes by downregulating MMP-13 [46]. Never-
theless, two recent studies have shown that BMP-7 fails to
inhibit TGF-β mediated fibrosis in the lung, skin and
renal tubular epithelial cells [27,28]. In our model, BMP-7
did not counteract the increase in ECM proteins induced
by TGF-β1. However, we have shown for the first time in
lung fibroblasts that BMP-7 reduces not only the basal
fibroblast-related expression of MMP-13 but also the
induced expression of this protein following stimulation
by TGF-β1. MMP-13, an interstitial collagenase, is the
principal enzyme involved in the initiation of collagen
breakdown. MMP-2 can serve as an activator of other
MMPs, namely MMP-13 [47]. Thus, the downregulation
of TGF-β1-induced MMP-2 activity by BMP-7 is in
accordance with the inhibition shown for MMP-13.
BMP-7 could contribute to a reduction in airway remod-
elling by inhibiting some MMPs without affecting ECM
protein release. BMP-7 was also able to counteract TGF-
β1-induced fibroblast differentiation. This potential regu-
latory function of BMP-7 confirms its ability to contrib-
ute to resolution of lung remodelling since increased
numbers of myofibroblasts and fibroblast differentiation
are major features of airway remodelling.
The role of BMP-4 in degradation and remodelling of
the ECM remains unclear, particularly in the lung. In fact,
little is known about the properties of BMP-4 either in
vivo or in vitro in the lung or other tissues. A regulatory
effect of BMP-4 on MMP-13 release in human adipocytes
has been reported [48] as well as an inhibition of cell pro-
liferation and an upregulation of αSMA expression in foe-
tal lung fibroblasts [30], but nothing is known of its
effects on adult lung fibroblasts. Here, we demonstrate
for the first time that BMP-4 is able to counteract the
increase in ECM protein release induced by TGF-β1 in
NHLF. We also reported that BMP-4 not only reduces the
basal fibroblast-related expression of MMP-13 but also its
expression induced by TGF-β1. The contribution of
BMP-4 to the reduction of airway remodelling could
result from a direct modulation of the production of
ECM proteins as well as MMP-13. In our study, BMP-4
Figure 6 TGF-β1-induced myofibroblast like phenotype in NHLF 
is partially inhibited by BMP-7. NHLF were stimulated with 5 ng/ml 
TGF-β1 or 100 ng/ml BMP-4 or BMP-7 or with TGF-β1 in the presence 
of BMP-4 or BMP-7 for 72 h. Representative panel of α-SMA expression 
was obtained by immunohistochemistry (A) and western blot of cell 
lysates for α-SMA is shown in (B). Data are representative of five inde-
pendent experiments.
- TGF-β1 + TGF-β1
A
TGF-β1 (5 ng/ml)
BMP-4 (100 ng/ml)
BMP-7 (100 ng/ml)
-+ - +
-
- +
-
-
--
+- - +
+ - +
42 kDa 
B
Figure 7 TGF-β1-induced CTGF promoter and SBE-SEAP reporter 
activities are not modulated by the BMPs. (A) The CTGF promoter 
pCT-sb was transiently transfected into NHLF, cells were then treated 
with 5 ng/ml TGF-β1 or 100 ng/ml BMP-4 or BMP-7 or with TGF-β1 in 
the presence of BMP-4 or BMP-7 in FGM containing 0.2% FBS. All assays 
were performed with 150000 cells/well in 2 ml total volume in 6-well 
plates and luciferase activity was measured after 24 h induction in 50 
μl cell pellet. (B) MFB-F11 cells stably transfected with SBE-SEAP were 
stimulated with 5 ng/ml TGF-β1 or 100 ng/ml BMP-4 or BMP-7 or with 
TGF-β1 in the presence of BMP-4 or BMP-7 in serum-free DMEM. All as-
says were performed with 40000 cells/well in 100 μl total volume in 96-
well plates and SEAP activity was measured after 24 h induction in 10 
μl supernatant. Data are mean ± SD of five independent experiments. 
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had no direct effect on fibroblast proliferation. This is in
contrast to the study of Jeffery et al. which reported inhi-
bition of fibroblast proliferation but their study was per-
formed on foetal fibroblasts which possess a higher
intrinsic capacity for self-renewal than adult cells. The
differential response of NHLF to BMP-4 and BMP-7 may
also be a function of the signalling pathways utilized or,
alternatively, the regulation of different transcriptional
repressors or activators. It is likely that BMP-4 and BMP-
7 act via different pathways to regulate ECM accumula-
tion. BMP-7 selectively binds to receptors distinct from
those of BMP-4: BMP-4 binds and activates ALK-3 and
ALK-6 whereas BMP-7 preferentially binds to ALK-2 and
ALK-6 [49-51]. Furthermore, the actions of the BMPs, at
least BMP-7, may be tissue or cell type specific since the
inhibitory effects of BMP-7 on remodelling are less pro-
nounced in the lung than other tissues.
Conclusions
Evidence from animal models suggests that airway
remodelling in asthma may be prevented or reversed
using agents which target TGF-β [8,52]. Therefore, mod-
ulation of TGF-β or its activity represents a potential
therapeutic target for asthma and other fibrotic diseases.
We were the first to report dysregulation of BMP and
BMPR expression in asthma [31]. Others have shown an
up-regulation of Gremlin, an inhibitor of BMP-4 signal-
ing pathways, in idiopathic pulmonary fibrosis and have
suggested that this increased expression of Gremlin may
be a key event in the persistence of myofibroblasts in the
lung interstitium [53]. Taken together, these data lend
weight to the argument that BMP-4 plays a crucial role in
the regulation of lung fibroblasts in disease. Our current
study has determined that BMP-7 can also exert some
functional effects on TGF-β1-driven profibrotic pro-
cesses in normal lung fibroblasts. These BMPs appear to
be attractive targets for therapeutic intervention in asth-
matic disease although the blockade of TGF-β1 by only
one of these molecules may not be sufficient to totally
inhibit activity. A better understanding of how BMPs act
in vitro on lung structural cells and in vivo in animal
models of asthma could potentially lead to the ameliora-
tion of airway remodelling and consequently a decrease
of asthma symptoms.
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